PSMA-targeted dendrimer as an efficient anticancer drug delivery vehicle for prostate cancer
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Researchers developed a novel nanoplatform (PD-CTT1298) for targeted prostate cancer (PCa) drug delivery. This PSMA-targeted dendrimer selectively delivers chemotherapy to PCa cells, enhancing efficacy and reducing side effects.
Area Of Science
- Nanomedicine
- Oncology
- Drug Delivery
Background
- Prostate cancer (PCa) poses a significant mortality risk, with limited treatment options for advanced stages due to challenges in selective drug delivery.
- While Prostate Specific Membrane Antigen (PSMA) is a target for PCa imaging and therapy, its use for chemotherapy delivery is not yet clinically successful.
Purpose Of The Study
- To develop a PSMA-targeted nanoplatform (PD-CTT1298) for the selective intracellular delivery of potent chemotherapeutics to PCa cells.
- To evaluate the efficacy of this nanoplatform in targeting PSMA-positive PCa and delivering anti-cancer agents.
Main Methods
- A generation 4 hydroxy polyamidoamine dendrimer (PD) was conjugated with an irreversible PSMA ligand (CTT1298) to create the PD-CTT1298 nanoplatform.
- PSMA binding affinity (IC50), cellular uptake in PSMA (+) PCa cells, tumor targeting in a mouse model, and in vitro anti-proliferative activity of conjugated cabozantinib were assessed.
Main Results
- PD-CTT1298-Cy5 demonstrated nanomolar PSMA binding affinity and selective uptake in PSMA (+) PCa cells via PSMA-mediated internalization.
- In vivo studies showed selective targeting of PSMA (+) tumors with rapid clearance from off-target organs, minimizing systemic side effects.
- Conjugation of cabozantinib to the nanoplatform significantly enhanced anti-proliferative activity compared to the free drug.
Conclusions
- The PD-CTT1298 nanoplatform offers a versatile approach for delivering high payloads of potent chemotherapeutics selectively to PCa.
- This strategy holds promise for improving treatment outcomes in PCa by enhancing efficacy and mitigating dose-related systemic side effects.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...